Oct 26, 2009 16:30 Icagen Reports Top-line Results of Phase IIa Study of Senicapoc in Exercise-Induced Asthma Icagen, Inc. (Nasdaq:ICGN) today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes. In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. The results of the pulmonary function tests were compared between the treatment groups, adjusting for differences in baseline values. continued... http://www.globenewswire.com/newsroom/headlines.html?max=20;start=20
Market Data 
Markets 
AI
